Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: results of the RBMDGELTAMO08 phase II trial

Bendamustine; Follicular lymphoma; Immunochemotherapy

Detalles Bibliográficos
Autores: Peñalver, Francisco‐Javier, Márquez, Jose‐Antonio, Durán, Soledad, Giraldo, Pilar, Martín, Alejandro, Montalbán, Carlos, López Hernández, Andrés
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:11351/5127
Acceso en línea:https://hdl.handle.net/11351/5127
http://hdl.handle.net/11351/5127
Access Level:acceso abierto
Palabra clave:Limfomes
Medicaments antineoplàstics
Prognosi
DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, Follicular
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Therapeutics::Drug Therapy::Drug Therapy, Combination::Antineoplastic Combined Chemotherapy Protocols
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma folicular
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::Diagnóstico::Pronóstico
id ES_608d41eff85cea385ecb92bd7d75d29c
oai_identifier_str oai:recercat.cat:11351/5127
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: results of the RBMDGELTAMO08 phase II trial
title Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: results of the RBMDGELTAMO08 phase II trial
spellingShingle Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: results of the RBMDGELTAMO08 phase II trial
Peñalver, Francisco‐Javier
Limfomes
Medicaments antineoplàstics
Prognosi
DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, Follicular
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Therapeutics::Drug Therapy::Drug Therapy, Combination::Antineoplastic Combined Chemotherapy Protocols
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma folicular
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::Diagnóstico::Pronóstico
title_short Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: results of the RBMDGELTAMO08 phase II trial
title_full Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: results of the RBMDGELTAMO08 phase II trial
title_fullStr Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: results of the RBMDGELTAMO08 phase II trial
title_full_unstemmed Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: results of the RBMDGELTAMO08 phase II trial
title_sort Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: results of the RBMDGELTAMO08 phase II trial
dc.creator.none.fl_str_mv Peñalver, Francisco‐Javier
Márquez, Jose‐Antonio
Durán, Soledad
Giraldo, Pilar
Martín, Alejandro
Montalbán, Carlos
López Hernández, Andrés
author Peñalver, Francisco‐Javier
author_facet Peñalver, Francisco‐Javier
Márquez, Jose‐Antonio
Durán, Soledad
Giraldo, Pilar
Martín, Alejandro
Montalbán, Carlos
López Hernández, Andrés
author_role author
author2 Márquez, Jose‐Antonio
Durán, Soledad
Giraldo, Pilar
Martín, Alejandro
Montalbán, Carlos
López Hernández, Andrés
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv [Peñalver FJ] Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain. [Márquez JA] Hospital de Basurto, Vizcaya, Spain. [Durán S] Complejo Hospitalario de Jaén, Jaén, Spain. [Giraldo P] Hospital Universitario Miguel Servet, Zaragoza, Spain. [Martín A] Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain. [Montalbán C] Hospital Universitario Ramón y Cajal, Madrid, Spain. [López A] Vall d'Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Limfomes
Medicaments antineoplàstics
Prognosi
DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, Follicular
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Therapeutics::Drug Therapy::Drug Therapy, Combination::Antineoplastic Combined Chemotherapy Protocols
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma folicular
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::Diagnóstico::Pronóstico
topic Limfomes
Medicaments antineoplàstics
Prognosi
DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, Follicular
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Therapeutics::Drug Therapy::Drug Therapy, Combination::Antineoplastic Combined Chemotherapy Protocols
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma folicular
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::Diagnóstico::Pronóstico
description Bendamustine; Follicular lymphoma; Immunochemotherapy
publishDate 2019
dc.date.none.fl_str_mv 2019
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/5127
http://hdl.handle.net/11351/5127
url https://hdl.handle.net/11351/5127
http://hdl.handle.net/11351/5127
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Cancer Medicine;8(16)
https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.2555
dc.rights.none.fl_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wiley Online Library
publisher.none.fl_str_mv Wiley Online Library
dc.source.none.fl_str_mv Scientia
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409315035545600
spelling Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: results of the RBMDGELTAMO08 phase II trialPeñalver, Francisco‐JavierMárquez, Jose‐AntonioDurán, SoledadGiraldo, PilarMartín, AlejandroMontalbán, CarlosLópez Hernández, AndrésLimfomesMedicaments antineoplàsticsPrognosiDISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, FollicularANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Therapeutics::Drug Therapy::Drug Therapy, Combination::Antineoplastic Combined Chemotherapy ProtocolsANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::PrognosisENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma folicularTÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinadaTÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::Diagnóstico::PronósticoBendamustine; Follicular lymphoma; ImmunochemotherapyBendamustina; Linfoma folicular; InmunoquimioterapiaBendamustina; Limfoma fol·licular; ImmunoquimioteràpiaBackground: Consensus is lacking regarding the optimal salvage therapy for patients with follicular lymphoma who relapse after or are refractory to immunochemotherapy. Methods: This phase II trial evaluated the efficacy and safety of response-adapted therapy with rituximab, bendamustine, mitoxantrone, and dexamethasone (RBMD) in follicular lymphoma patients who relapsed after or were refractory to first-line immunochemotherapy. Sixty patients received three treatment cycles, and depending on their response received an additional one (complete/unconfirmed complete response) or three (partial response) cycles. Patients who responded to induction received rituximab maintenance therapy for 2 years. Results: Thirty-three (55%) and 42 (70%) patients achieved complete/unconfirmed complete response after three cycles and on completing induction therapy (4-6 cycles), respectively (final overall response rate, 88.3%). Median progression-free survival was 56.4 months (median follow-up, 28.3 months; 95% CI, 15.6-51.2). Overall survival was not reached. Progression-free survival did not differ between patients who received four vs six cycles (P = .6665), nor between patients who did/did not receive rituximab maintenance after first-line therapy (P = .5790). Median progression-free survival in the 10 refractory patients was 25.5 months (95% CI, 0.6-N/A) and was longer in patients who had shown progression of disease after 24 months of first-line therapy (median, 56.4 months; 95% CI, 19.8-56.4) than in those who showed early progression (median, 42.31 months; 95% CI, 24.41-NA) (P = .4258). Thirty-six (60%) patients had grade 3/4 neutropenia. Grade 3/4 febrile neutropenia and infection were recorded during induction (4/60 [6.7%] and 5/60 [8.3%] patients, respectively) and maintenance (2/43 [4.5%] and 4/43 [9.1%] patients, respectively). Conclusions: This response-adapted treatment with RBMD followed by rituximab maintenance is an effective and well-tolerated salvage treatment for relapsed/refractory follicular lymphoma following first-line immunochemotherapy. Clinical trial registration: ClinicalTrials.gov # NCT01133158Financial support was provided by Mundipharma Spain and Roche Pharma Spain.Wiley Online Library[Peñalver FJ] Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain. [Márquez JA] Hospital de Basurto, Vizcaya, Spain. [Durán S] Complejo Hospitalario de Jaén, Jaén, Spain. [Giraldo P] Hospital Universitario Miguel Servet, Zaragoza, Spain. [Martín A] Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain. [Montalbán C] Hospital Universitario Ramón y Cajal, Madrid, Spain. [López A] Vall d'Hebron Hospital Universitari, Barcelona, SpainVall d'Hebron Barcelona Hospital Campus202020202019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/5127http://hdl.handle.net/11351/5127Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésCancer Medicine;8(16)https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.2555Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/51272026-05-29T05:05:01Z
score 15,811543

Similares en LA Referencia